X4 Pharmaceuticals, Inc.
XFOR
$0.19
$0.00281.50%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -108.16% | -1,492.02% | 263.04% | -115.51% | 34.27% |
| Total Depreciation and Amortization | 340.32% | 156.73% | 53.97% | -51.18% | -50.00% |
| Total Amortization of Deferred Charges | -18.95% | -20.16% | -2.82% | 12.89% | -6.42% |
| Total Other Non-Cash Items | 244.47% | 117.23% | -478.25% | 555.58% | -186.06% |
| Change in Net Operating Assets | 122.32% | -146.86% | -32.21% | 239.29% | -197.86% |
| Cash from Operations | -18.91% | -63.40% | -41.32% | -26.72% | -45.33% |
| Capital Expenditure | -17.14% | -1,050.00% | -1,575.00% | -555.56% | -2.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -78.82% | -207.57% | -64.15% | -- | -- |
| Cash from Investing | -78.38% | -208.88% | 2,083.25% | -59,033.33% | -14,114.71% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 39.18% | -- | -99.77% | -- | -99.84% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | 39.18% | -100.00% | -70.93% | -- | -99.84% |
| Foreign Exchange rate Adjustments | -292.13% | 329.17% | -200.00% | -218.00% | -65.01% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -28.96% | -926.30% | 101.58% | -36.31% | -177.26% |